Arcus Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
RCUS$18.95+3.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In millions, except per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenues: | |||
| License and development services(Includes $214, $207 and $75 from a related party) | $221 | $222 | $80 |
| Other collaboration(Includes $26, $36 and $37 from a related party) | 26 | 36 | 37 |
| Total revenues | 247 | 258 | 117 |
| Operating expenses: | |||
| Research and development(Includes $25, ($39) and ($110) payments to/(from) a related party) | 523 | 448 | 340 |
| General and administrative(Includes $5, $2 and $— payments to a related party) | 110 | 120 | 117 |
| Impairment of long-lived assets (see Note 14, Leases) | — | 20 | — |
| Total operating expenses | 633 | 588 | 457 |
| Loss from operations | (386) | (330) | (340) |
| Non-operating income (expense): | |||
| Interest and other income, net | 41 | 52 | 41 |
| Interest expense | (8) | (4) | (2) |
| Total non-operating income, net | 33 | 48 | 39 |
| Loss before income taxes | (353) | (282) | (301) |
| Income tax expense | — | (1) | (6) |
| Net loss | $(353) | $(283) | $(307) |
| Net loss per share: | |||
| Basic and diluted | $(3.29) | $(3.14) | $(4.15) |
| Shares used to compute net loss per share: | |||
| Basic and diluted | 107.4 | 90.1 | 74.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.